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Abstract
Background: The DM domain is a zinc finger-like DNA binding motif first identified in the sexual
regulatory proteins Doublesex (DSX) and MAB-3, and is widely conserved among metazoans. DM
domain proteins regulate sexual differentiation in at least three phyla and also control other aspects
of development, including vertebrate segmentation. Most DM domain proteins share little similarity
outside the DM domain. DSX and MAB-3 bind partially overlapping DNA sequences, and DSX has
been shown to interact with DNA via the minor groove without inducing DNA bending. DSX and
MAB-3 exhibit unusually high DNA sequence specificity relative to other minor groove binding
proteins. No detailed analysis of DNA binding by the seven vertebrate DM domain proteins,
DMRT1-DMRT7 has been reported, and thus it is unknown whether they recognize similar or
diverse DNA sequences.
Results: We used a random oligonucleotide in vitro selection method to determine DNA binding
sites for six of the seven proteins. These proteins selected sites resembling that of DSX despite
differences in the sequence of the DM domain recognition helix, but they varied in binding efficiency
and in preferences for particular nucleotides, and some behaved anomalously in gel mobility shift
assays. DMRT1 protein from mouse testis extracts binds the sequence we determined, and the
DMRT proteins can bind their in vitro-defined sites in transfected cells. We also find that some
DMRT proteins can bind DNA as heterodimers.
Conclusion: Our results suggest that target gene specificity of the DMRT proteins does not derive
exclusively from major differences in DNA binding specificity. Instead target specificity may come
from more subtle differences in DNA binding preference between different homodimers, together
with differences in binding specificity between homodimers versus heterodimers.
Background
Sexual reproduction is widespread among metazoans,
and hence sexual dimorphisms of anatomy, physiology
and behavior that promote efficient reproduction also
occur widely. Despite the broad occurrence of sexual
dimorphism, most regulators of sex-specific development
that have been described appear to function in relatively
restricted groups of animals, suggesting that their involve-
ment in this process either is evolutionarily recent or has
not been widely maintained. Transcription factors con-
taining the DM domain are an exception, with family
members thus far shown to control sexual development in
at least three metazoan phyla (insects, nematodes, and
vertebrates) [1,2]. In Drosophila, the Doublesex (Dsx) gene
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controls most aspects of sexual differentiation, function-
ing in both sexes via sex-specific protein isoforms gener-
ated by alternative splicing [3,4]. In C. elegans, mab-3 [5,6]
and mab-23 [7] direct aspects of male differentiation. The
related gene Dmrt1 is required for testicular differentia-
tion in mice [8] and is sex-specifically expressed in other
vertebrates with varied sex determination mechanisms [9-
11]. In humans, hemizygosity in the chromosomal region
containing DMRT1, DMRT3 and DMRT2 (9p24.3) is asso-
ciated with human testicular dysgenesis and XY male-to-
female sex reversal [12-16]. DM domain proteins also
may play a role in human cancer: amplification and over-
expression of DMRT1  is associated with spermatocytic
seminoma [17]. The role of this gene family is not limited
to sexual differentiation, however: Dmrt2 is a critical regu-
lator of vertebrate segmentation [18-20], and Dmrt4 has
been implicated in olfactory placode neurogenesis in
amphibians [21] as well as in ovarian folliculogenesis in
mice [22].
The DM domain is an intertwined zinc finger-like DNA
binding module [23] first identified in Dsx [24] and sub-
sequently found in mab-3 [25]. Dsx and mab-3 control sev-
eral analogous sexual dimorphisms and the male-specific
isoform of DSX (DSX-M) can substitute for MAB-3 in the
developing C. elegans male nervous system [6,25,26]. The
ability of DSX-M to regulate at least one MAB-3 target gene
implies that the two proteins must be able to bind a sim-
ilar DNA sequence. Indeed, in vitro determinations of
binding site preference and identification of in vivo bind-
ing sites for the two proteins confirm that they bind dis-
tinct but overlapping sequences [24,26,27]. The ability of
DSX and MAB-3 to bind the same site in vivo is remarka-
ble given the differences in domain organization between
the proteins. DSX has a single DM domain and binds
DNA as a dimer [28-30], whereas MAB-3 has tandem DM
domains, both of which are required for function [25],
and binds an asymmetric site, probably as a monomer
[26].
The DM domain is notable not only for its apparently
ancient and conserved role in regulating sexual differenti-
ation, but also for its unusual structure and mode of DNA
interaction. The solution structure of a DSX DM domain
peptide was determined and found to be an intertwined
module coordinating two zinc atoms, unrelated to struc-
tures of other zinc finger motifs [23]. Moreover, base sub-
stitution experiments indicate that the DM domain differs
from other zinc finger motifs in interacting with DNA pri-
marily via the minor rather than the major groove [23].
Mutational analysis suggests that the DM domain inter-
acts with DNA via the zinc binding module and a C-termi-
nal tail that mediates high-affinity DNA recognition [31].
Structural studies suggest that the C-terminal tail is a nas-
cent alpha helix that becomes ordered upon DNA binding
and may widen the minor groove without bending DNA
[23]. This mode of interaction with the minor groove is
unusual and may be analogous to that of the T box motif
[32].
Minor groove binding by DM domain proteins appears to
permit them to bind DNA on sites overlapping those of
major groove binding proteins. The best studied example
is that of DSX binding to an enhancer site in the Yp1 yolk
protein gene, which contains a binding site for an uniden-
tified bZip protein. DSX-F cooperates with this protein to
activate  Yp1  transcription in females, while DSX-M is
thought to antagonize this protein, helping ensure that
Yp1  is not transcribed in males [33]. The mechanisms
involved in these functional interactions are unknown.
DSX-M has a larger C-terminal domain than DSX-F, so it
has been suggested that DSX-F forms an activating com-
plex with the bZIP and perhaps other proteins, whereas
DSX-M may physically occlude binding by the bZIP pro-
tein [33]. Interference by DM domain proteins with over-
lapping transcriptional activators may be a conserved
feature: mutational analysis of a regulatory site in the C.
elegans ref-1 gene indicates that MAB-3 represses transcrip-
tion of ref-1  in part by antagonizing activation by an
unknown protein that binds an overlapping site [27].
All higher metazoan species examined have multiple DM
domain genes, for example four in Drosophila, eleven in C.
elegans, and seven in mammals. How DM domain pro-
teins achieve specificity for target genes is unknown, but
could derive from differences in DNA binding specificity,
expression pattern, covalent modifications, interaction
with cofactors, or a combination of these. DNA binding
specificity has been reported for DSX and MAB-3, as
described above. Although these proteins bind related
sites, their preferred DNA sequences are sufficiently differ-
ent that oligonucleotides can readily be designed to bind
one but not the other [26]. This is not surprising given the
structural differences between DSX and MAB-3, but most
DM domain proteins, like DSX, have a single DM domain
and thus may bind sites more closely related to that of
DSX. A synthetic DMRT1 DM domain peptide has been
shown to bind a DSX site, albeit with relatively low affin-
ity [23]. However, no detailed analysis of binding specifi-
city has been performed for any vertebrate DM domain
protein.
Here we have investigated DNA binding by the mamma-
lian DM domain proteins. We used an in vitro random
oligonucleotide selection method to determine the pre-
ferred DNA binding sites of six of the seven mouse DM
domain proteins, as well as human DMRT1. We find that
these proteins select very similar DNA sequences despite
differences in the primary sequence of the DM domain.
We also find that DM domain proteins can heterodimer-BMC Molecular Biology 2007, 8:58 http://www.biomedcentral.com/1471-2199/8/58
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ize on DNA, demonstrating that combinatorial regulation
of individual target sites by these proteins is possible. Our
results indicate that the target site specificity of this impor-
tant family of regulatory proteins is unlikely to derive
entirely from innate DNA binding specificity.
Results
DNA binding specificity of DMRT1
To define high-affinity DNA binding sites for mouse
DMRT1, we used a selection method in which bound oli-
gonucleotides are isolated from a large pool of random
double-stranded oligonucleotides by immunoprecipita-
tion of protein/DNA complexes [34]. Recovered DNA is
amplified by PCR using flanking primers and reselected to
further enrich for high-affinity binding sites. Full-length
DMRT1 protein was made by in vitro transcription/trans-
lation and contained an amino-terminal Myc epitope tag.
After three rounds of DNA binding and immunoprecipi-
tation, a final selection was performed using a gel mobil-
ity shift, and the shifted oligonucleotides were cloned and
sequenced. DNA sequences of the selected oligonucle-
otides were compared using the Gibbs Motif Sampler
algorithm [35,36] to identify potential binding site prefer-
ences (Methods). This revealed a consensus sequence
(Figure 1A) closely resembling that bound by DSX [29]
and also similar to the site bound by MAB-3 [26]. Like the
previously determined DSX consensus, the DMRT1 site
contains an inverted repeat of six nucleotides flanking a
central A/T basepair (position 0). The most obvious differ-
ence between the sites is that DMRT1 always selected a G
at position -6 whereas DSX lacked a strong preference at
this position (see Figure 2A and Additional file 1). Com-
petitive gel mobility shift assays (Figure 1B, described
below; and data not shown) confirmed that this repre-
sents a real difference in binding preference between the
two proteins, as introducing a C at this position severely
compromised binding by DMRT1 but not DSX. The
DMRT1 site is partially asymmetric: selection of preferred
nucleotides extends further on the left side of the inverted
repeat than on the right side (as oriented in Figure 1A). An
analogous site selection using human DMRT1 protein
identified a nearly identical binding site (not shown).
To verify that DMRT1 binds to the selected consensus, we
used a competitive gel mobility shift assay (Figure 1B). We
made a set of unlabeled competitor double-stranded oli-
gonucleotides, each with a single position of the binding
site changed to the least-preferred nucleotide or one that
was never selected. We assayed the ability of these altered
sites to compete for DMRT1 binding against a labeled
probe that conforms to the binding site consensus. At the
competitor concentrations used, a competitor with an
unaltered binding site ("self" in Figure 1B) strongly
reduces binding to the labeled probe. Therefore, a strong
shifted band indicates that a change in that nucleotide
eliminates effective competition by the unlabeled DNA.
All single base changes to nucleotides that were never
selected reduced binding, with the strongest affects within
the core 13 bp inverted repeat sequence. One position
outside the 13 bp core (-8) was strongly preferred, and
changing this to a non-selected nucleotide strongly
reduced binding. Based on these results, the binding con-
sensus matrix appears to sensitively reflect the binding
preference of DMRT1, at least in vitro. The close similarity
of the DMRT1 site to a DSX site is consistent with the pre-
vious observation that the DMRT1 DM domain can
weakly bind to a DSX site [23]. Like DSX [23,29], DMRT1
appears to bind DNA as a dimer. This is supported by het-
erodimerization experiments using proteins of different
sizes (see below). Even at limiting protein concentrations
DMRT1 preferentially forms dimers rather than mono-
mers on DNA (Figure 1C), indicating that binding of the
first molecule facilitates binding of the second.
We next tested whether the site defined using in vitro
translated protein is bound by endogenous DMRT1 from
testis nuclear extracts. Testis extracts shift a DMRT1 site
probe to the same electrophoretic mobility as the complex
formed with in vitro translated DMRT1 (Figure 1D). This
complex is super-shifted by a DMRT1 antibody, confirm-
ing the presence of DMRT1 in the complex. We also tested
human DMRT1 binding in transfected cells using a fusion
of DMRT1 to the VP16 strong transcriptional activation
domain. (DMRT1 lacking VP16 had no specific effect on
reporter expression in this cell type.) HEK293 cells trans-
fected with a luciferase reporter containing a single
DMRT1 binding site show strong transcriptional activa-
tion when co-transfected with a vector expressing DMRT1-
VP16, but not when transfected with a vector expressing
VP16 alone (Figure 1E). Previous work identified several
amino acid residues in the DSX DM domain that are crit-
ical for DNA binding and cause loss-of-function mutant
phenotypes [29,31]. Mutating DMRT1-VP16 at one of
these positions (R123A; equivalent to R91 in DSX) nearly
abolishes reporter activation, even when the mutant pro-
tein is expressed at a higher level than the wild type pro-
tein (Figure 1E and data not shown).
Binding specificity of other DMRT proteins
The preceding results show that the in vitro binding site
selection strategy we used for DMRT1 can identify a high-
affinity binding site capable of interaction in vitro and in
cultured cells. To compare DNA binding specificity
among DM domain proteins, we next selected binding
sites for the other six mouse DMRT proteins, and were
able to define binding site consensus sequences for all
except DMRT6. The other five proteins selected sites that
can be aligned with DMRT1 and DSX [26,29] sites, with
the closest similarity on one side of the 13 bp core DMRT1
consensus sequence (Figure 2A and Additional file 1).BMC Molecular Biology 2007, 8:58 http://www.biomedcentral.com/1471-2199/8/58
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DNA binding specificity of DMRT1 Figure 1
DNA binding specificity of DMRT1. (A) Summary of binding site selection. Top panel shows percentage of occurrence of 
each nucleotide at each position of 22 selected oligonucleotides. (At some positions percentages do not total 100, due to 
rounding to nearest integer.) Below the selection matrix is a comparison of the DMRT1 binding consensus to those of DSX 
[29] and MAB-3 [26]. (B) Test of DMRT1 DNA binding specificity. Competitive gel mobility shift assay in which labeled dsDNA 
probe matching DMRT1 binding consensus is competed with 40-fold excess of unlabelled dsDNA, either unaltered ("SELF") or 
containing the indicated sequence changes (positions align with those shown in panel A). Only the shifted DMRT1/DNA com-
plex is shown. Darker bands indicate weaker competition. (C) Preferential binding to DNA by DMRT1 as a dimer. Gel mobility 
shift using increasing amounts of in vitro translated DMRT1 protein to shift a constant amount of labeled dsDNA. Positions of 
complexes containing monomer ("M") or dimer ("D") of DMRT1 are indicated. (D) DNA binding by DMRT1 from mouse tes-
tis. Gel mobility shift using in vitro translated DMRT1 (left) or mouse testis nuclear extract (right) to shift labeled dsDNA con-
taining DMRT1 binding consensus. Addition of water or pre-immune rabbit serum does not affect shifted band, but addition of 
anti-DMRT1 immune serum [8] super-shifts the band into the gel well. (E) DMRT1 DNA recognition in cultured cells. Luci-
ferase assay results shown for HEK293 cells transfected with expression vectors encoding only VP16, encoding DMRT1-VP16, 
or encoding DMRT1-VP16 with a missense mutation in the DM domain (R123A). Cells were co-transfected with a reporter 
plasmid containing four DMRT1 binding sites. Values shown are average of two experiments, with error bar indicating standard 
error of mean.BMC Molecular Biology 2007, 8:58 http://www.biomedcentral.com/1471-2199/8/58
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DNA binding specificity of other DMRT proteins Figure 2
DNA binding specificity of other DMRT proteins. (A) Summary of in vitro random oligonucleotide binding site selec-
tions for DMRT1, 2, 3, 4, 5, and 7. Sequence preference for DSX is from Yi et al., 1999 [26], reanalyzed using the Gibbs Motif 
Sampler program [35, 36]. Sequence preferences are displayed using the WebLogo program [44, 45] to indicate preferences at 
each position, with size of letter indicating information content of each nucleotide (bits). The selected sequences from which 
each consensus was derived are shown in Supplemental Figure 1. (B,C) Gel mobility shift analysis. (B) DMRT3 and DMRT5. (C) 
DMRT2, DMRT4, DMRT7. Labeled probes used are indicated below each panel, and proteins and antibodies present in binding 
reactions are indicated above. Mobility of dimer and monomer complexes with DNA are indicated for each protein ("M" or 
"D"); "NS" indicates non-specific complexes. Exposure time for panel C is 28-fold longer than for panel B. (D) DNA recogni-
tion by DMRT proteins in cultured cells. Transactivation by VP16 fusion proteins in HEK293 cells transfected with expression 
vectors encoding the indicated DMRT-VP16 fusions and with the pGL3-Promoter reporter plasmid containing a single DMRT 
consensus sequence upstream of the luciferase coding sequence. Values shown are average of two experiments, with error bar 
indicating standard error of the mean.BMC Molecular Biology 2007, 8:58 http://www.biomedcentral.com/1471-2199/8/58
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Consistent with this similarity, all five proteins can shift a
DMRT1 consensus site to varying degrees in a gel mobility
assay (Figure 2B,C).
The proteins differed greatly in how readily they selected
oligonucleotides containing binding sites and in their
behavior in the gel mobility shift assay. DMRT5 selected a
consensus sequence after two rounds of immunoprecipi-
tation followed by a gel shift, while DMRT3, like DMRT1,
required three rounds. In contrast, DMRT2 and DMRT7
required five rounds of immunoprecipitation prior to the
gel shift. DMRT4 did not show a shifted band in the gel
shift assay even after five rounds of immunoprecipitation,
and thus its binding preference was determined by
sequencing oligonucleotide pools after the fifth round of
immunoprecipitation. DMRT3 and DMRT5 efficiently
formed protein/DNA complexes that could be super-
shifted with the 9E10 anti-Myc antibody (Figure 2B).
Although DMRT5 selected a consensus in just two rounds,
it bound a site conforming to this consensus less effi-
ciently than it bound a DMRT1 site. This indicates that the
DMRT5 oligonucleotide pool had not fully evolved
toward high affinity sites after two rounds. DMRT2 and
DMRT7 also formed specific protein/DNA complexes
with either their cognate sites or a DMRT1 site, but DNA
binding by these proteins was much less efficient than
that of DMRT1 (Figure 2C; note 28-fold longer exposure
time relative to Figure 2B). DMRT4 weakly shifted a
DMRT4 probe, but on a DMRT1 site it formed complexes
that failed to enter the gel (Figure 2C). As lysates pro-
grammed with other DMRT proteins did not form these
complexes, we conclude that they contain DMRT4, possi-
bly in a high-order complex or aggregate.
It is unclear why the DMRT2, DMRT4, and DMRT7 pro-
teins behaved differently from the others, as all were
expressed at similar levels (data not shown) and selec-
tions were performed in parallel under identical condi-
tions. Possibly this reflects differences among the DMRT
proteins in optimal DNA binding conditions or in their
mode of DNA interaction, as appears to be the case with
DMRT4 on a DMRT1 site. Despite these differences in
binding behavior, all six proteins when fused to VP16 can
activate transcription from their selected sites in trans-
fected HEK293 cells (Figure 2D). The magnitude of activa-
tion varied between experiments, but DMRT1 consistently
showed the strongest activation, followed by DMRT3 and
DMRT5, with DMRT2, DMRT4, and DMRT7 showing the
weakest activation.
DMRT1, DMRT3, and DMRT5 all selected sites readily and
bound efficiently. Although similar, the binding sites
selected were not identical. Also, DMRT3 selected a site to
which it primarily binds as a monomer (Figure 2B), sug-
gesting that this protein may have higher monomeric
DNA binding affinity than the other DMRT proteins. This
does not represent an absolute preference for monomer
binding, however, as DMRT3 preferentially binds as a
dimer to a DMRT1 site (Figure 2B).
We next investigated the extent of similarity in DNA bind-
ing specificity between DMRT1 and DMRT5. To do this,
we first repeated the competitive gel mobility shift assay of
Figure 1A, this time testing binding of DMRT5 to a labeled
DMRT1 site. We asked whether the same set of unlabeled
competitor DNAs had the same or different effects on
binding of DMRT1 (Figure 1A) and DMRT5 (Figure 3A).
Quantitation of the gel assays in Figures 1A and 3A is
shown graphically in Figure 3B, which indicates how well
each altered oligonucleotide competes, relative to an
unaltered oligonucleotide. It is apparent from this analy-
sis that base changes in the left half of the core binding site
(-1 to -6, except -4) affect DNA binding of both proteins
more severely than those on the right side (+1 to +6). This
suggests a more critical role for the left side in DNA bind-
ing by both proteins. This analysis also highlights one
position (-8) that appears to be particularly important in
discriminating between binding by the two proteins.
DMRT1 never selected a G at -8 and does not tolerate one.
In contrast, DMRT5 occasionally selected a G at -8 (6% of
sites) and can tolerate one. This confirms that the pre-
ferred binding sites of DMRT1 and DMRT5, while similar,
are not identical, suggesting that they do not regulate
identical sets of target genes.
The observation that the nucleotide identity at position -8
discriminates between binding of DMRT1 versus DMRT5
led us to investigate other positions at which nucleotide
identity might be discriminatory for these two proteins.
We selected six additional positions at which there was a
significant difference in nucleotide preferences between
DMRT1 and DMRT5, and tested the effect of changes at
these positions on DNA binding, assayed by competitive
gel shift analysis (Figure 4A, B). We focused on positions
at which a particular nucleotide was selected more fre-
quently by DMRT5 than by DMRT1. When a particular
nucleotide was never selected by DMRT1, making that
change had a stronger effect on binding by DMRT1 than
on binding by DMRT5 (Figure 4B, positions -8G, 0G,
+3G, and +4C). By contrast, when a particular nucleotide
was occasionally selected by DMRT1, making that change
had a modest effect on binding by both proteins. For
example, at position -8, a C, which is occasionally selected
by both proteins, had little or no effect on binding by
either protein. From these results we conclude that the
DMRT1 and DMRT5 DNA binding preferences are very
similar, but that specific nucleotides can discriminate
between binding of the two proteins. This systematic com-
parison also indicates that the binding site selection is anBMC Molecular Biology 2007, 8:58 http://www.biomedcentral.com/1471-2199/8/58
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accurate indication of DNA site preference for these pro-
teins, at least in vitro.
Based on the site selection data, in which the left side of
each site was more strongly selected by DMRT1 and
DMRT5 than the right side, we hypothesized that protein
dimer formation might occur via initial binding to the left
side of the site, followed by recruitment of a second mon-
omer to the right side. A prediction of this model is that
sequence changes on the left side of the site that reduce
protein binding should not block dimer formation,
whereas changes to the right side should primarily reduce
dimer formation without strongly affecting monomer
binding. We tested six sequence changes, and found that
their effects on binding by both proteins are consistent
with this model (Figure 5).
Comparison of DNA binding preferences of DMRT1 and DMRT5 Figure 3
Comparison of DNA binding preferences of DMRT1 and DMRT5. Top panel: competitive gel mobility shift using the 
same probe and competitors as in Figure 1A, testing binding by in vitro translated DMRT5. Positions of monomeric and 
dimeric complexes are indicated ("M" or "D"). Bottom panel: effectiveness of competitor DNAs. Quantitation of data from top 
panel and Figure 1A, with competition by perfect DMRT1 site ("SELF") set at 1.0.BMC Molecular Biology 2007, 8:58 http://www.biomedcentral.com/1471-2199/8/58
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Nucleotides that discriminate between binding by DMRT1 and DMRT5 Figure 4
Nucleotides that discriminate between binding by DMRT1 and DMRT5. (A) Comparison of sites selected by DMRT1 
and DMRT5. WebLogo representation of frequency of occurrence of each base at each position in oligonucleotides selected by 
DMRT1 and DMRT5. Boxed residues are those selected by DMRT5 and not by DMRT1. (B) Competitive gel mobility shift 
assay results. Ability of unlabeled DNAs with the indicated changes to compete for binding with a labeled DMRT1 site DNA is 
plotted for each protein. Competition by an unaltered ("SELF") unlabelled DNA is set at 1.0 for each protein.BMC Molecular Biology 2007, 8:58 http://www.biomedcentral.com/1471-2199/8/58
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Heterodimerization of DMRT proteins
As described above, the DMRT proteins bind very similar
inverted repeat sequences. DSX has been shown to bind
its site cooperatively as a dimer. Dimerization motifs have
been mapped to the DM domain and to a C terminal
domain [28,29]. The DMRT proteins also appear to bind
as dimers and may in some cases be co-expressed [37],
raising the possibility of heterodimerization between
DMRT proteins. We therefore tested whether the DMRT
proteins can form heterodimers on DNA.
We examined heterodimerization by gel mobility shift
analysis. We tested binding of DMRT1 to its consensus
site, either alone or in the presence of a Myc-tagged DMRT
protein. To determine the composition of the resulting
DNA/protein complexes, we used either a DMRT1 or an
anti-Myc (9E10) antibody. We focused on DMRT3 and
DMRT5 as potential dimer partners, as they bind effi-
ciently to a DMRT1 site. When DMRT1 and DMRT3 were
present in the same binding reaction, we observed a com-
plex intermediate in electrophoretic mobility between the
homodimeric complexes formed by each of the proteins
alone (Figure 6). The putative heterodimer complex was
supershifted by both DMRT1 and anti-Myc antibodies,
demonstrating that it contains DMRT1 and DMRT3.
DMRT1 and DMRT5 also formed heterodimeric com-
plexes with DNA (see Additional file 2). We therefore con-
clude that DMRT1 can form heterodimers on DNA with
DMRT3 and with DMRT5, at least in vitro.
Discussion
We have used an in vitro DNA binding site selection pro-
cedure to define the binding site preferences for six of the
seven mouse DMRT proteins. The main conclusions of the
work presented here are that the DMRT proteins select
similar DNA binding consensus sites, which resemble that
of DSX, and that some DMRT proteins can heterodimerize
on DNA. The sites selected by the different proteins were
not identical, however, and we observed qualitative and
quantitative differences in DNA binding behavior in gel
mobility shift assays. These differences may have implica-
tions for DNA binding in vivo, as discussed below.
The DM domain is bipartite, comprised of an amino-ter-
minal zinc-binding module and a more variable carboxy-
terminal domain that has been proposed to act as a recog-
nition helix, contributing to DNA binding affinity and
specificity [23,31]. Mutagenesis studies have identified a
number of residues in both portions of the DSX DM
domain that are critical for binding to its consensus site
[38]. The DMRT proteins have recognition helices that dif-
fer from that of DSX at three of these critical positions.
Despite these differences, however, most of the DMRT
proteins select a site similar to that of DSX, and indeed
several can efficiently bind a DSX site in a gel shift assay
(data not shown). The similarity in DNA binding is sur-
prising, given that all of the DMRT proteins have an
amino acid change that eliminates efficient DNA binding
by DSX (D78E in DSX) [38]. The ability of the DSX and
DMRT DM domains, despite their different recognition
helices, to bind similar sequences underscores the need
for a DM domain/DNA co-structure to help define how
specific DM domain residues contribute to DNA affinity
and to DNA sequence specificity. It also will be interesting
to determine the preferred sites of more highly divergent
DM domains such as those found in C. elegans and see
whether they also bind sites similar to that of DSX.
The sites selected by the DMRT proteins were very similar
and most of the DMRT proteins were able to shift a
DMRT1 site in the gel shift assay. However there were dis-
tinct sequence preferences at some positions. We tested
the significance of the differences in sites selected by
DMRT1 and DMRT5, and confirmed that several differen-
tially selected nucleotides do have differential effects on
binding by the two proteins in a gel shift assay (Figures 3
and 4). Based on these comparisons, it therefore appears
that there are distinct binding preferences among the
Monomer versus dimer binding by DMRT1 and DMRT5 Figure 5
Monomer versus dimer binding by DMRT1 and 
DMRT5. Binding of DMRT1 and DMRT5 to labeled probes 
with single base changes from the DMRT1 consensus. In vitro 
translated protein used is indicated, as is position of mono-
meric and dimeric complexes for each protein.BMC Molecular Biology 2007, 8:58 http://www.biomedcentral.com/1471-2199/8/58
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DMRT proteins, at least in vitro. The extent to which such
differences in sequence preference also exist in vivo will
require the future identification and characterization of
DMRT target genes.
As described earlier, we were able to select bound DNA in
solution using all of the DMRT proteins except DMRT6,
but there were differences in the behavior of several pro-
teins in the gel mobility shift assay that may be significant.
DMRT2 and DMRT7 selected sites resembling those of the
other DMRT proteins and DSX, indicating similar specifi-
city, but exhibited less efficient DNA binding in the gel
mobility shift assay, suggesting lower affinity for DNA.
Although similar amounts of each protein were tested, we
cannot exclude the alternative possibility that some of the
proteins folded inefficiently and thus were less active. In
contrast to the other proteins tested, DMRT4 formed a
protein/DNA complex on a DMRT1 site that was excluded
from the gel. There are several possible explanations for
these differences in DNA binding behavior, which are not
mutually exclusive. First, some of the proteins may form
structurally distinct protein/DNA complexes, and this
may be reflected in their behavior in the gel shift assay. For
example, DMRT4 may form higher-order multimers on
DNA. Second, efficient binding of proteins like DMRT2
and DMRT7 may require covalent modifications that were
missing from the in vitro translated proteins. Third, some
of the proteins may normally bind DNA in conjunction
with one or more partner proteins (DM domain or other-
wise) that were missing from the in vitro assay. A possible
example is the efficient binding of DMRT3 as a het-
erodimer with DMRT1 (see below).
The DMRT protein binding sites, like that of DSX, com-
prise a punctuated palindrome flanking a single A/T base
pair, and we found that DMRT1 and DMRT5 bind to this
site as dimers. The site is not fully symmetrical, however,
and there was stronger selection of DNA sequence on one
side of most sites. Extensive sequence substitutions indi-
cated that the side with the stronger selection is required
for efficient DNA binding of both monomers and dimers,
whereas the other side is primarily needed to allow dimer
binding. Our data suggest a model in which the left side
of the binding site is recognized first by a DMRT mono-
mer. Once the first DMRT molecule has bound to the
DNA, it presents a surface that in combination with the
right side of the DNA site creates a high affinity binding
site, which, allows a second DMRT molecule to efficiently
bind. This model is supported by the base substitution
experiments in Figure 4C.
We found that DMRT1 can heterodimerize on DNA with
DMRT3 and DMRT5, raising the possibility of combinato-
rial gene regulation by DMRT proteins. It is particularly
striking that DMRT3 preferentially binds as a heterodimer
in vitro. Comprehensive expression analysis has not been
reported for most Dmrt genes, but it is clear that at least
some overlapping expression occurs. For example, Dmrt1
and Dmrt3 are coexpressed in spermatogonia and Sertoli
cells in the adult testis (unpublished data and the Mam-
malian Reproductive Genetics  Database). Because the
DMRT proteins vary in sequence preference outside the
core consensus (Figure 2A), heterodimer formation has
the potential to significantly increase selectivity for spe-
cific target sites. In addition, because the carboxy termini
of the DMRT proteins are highly variable, it is possible
that heterodimers can interact with a different spectrum of
transcriptional regulatory partner proteins than do
homodimers. It will be of interest in the future to better
define the overlap of DM domain protein expression in
mammals and other animals and to test the effect of het-
erodimerization on DNA binding specificity.
In contrast with the other DMRT proteins, DMRT6 did not
select binding sites, and we were unable to detect binding
of DMRT6 to a DMRT1 site (not shown). The other DMRT
Heterodimer formation between DMRT1 and DMRT3 Figure 6
Heterodimer formation between DMRT1 and 
DMRT3. Gel mobility shifts using labeled DMRT1 consensus 
probe DNA and indicated in vitro translated proteins. Posi-
tions of monomeric, and homo- and heterodimeric com-
plexes with DNA are indicated (maroon triangles indicate 
DMRT1 and gold triangles indicate DMRT3). DMRT3 protein 
is tagged with a myc epitope recognized by 9E10 monoclonal 
antibody. As shown in first two lanes, 9E10 does not affect 
complex formed by DMRT1, and anti-DMRT1 antibody does 
not affect complex formed by tagged DMRT3.BMC Molecular Biology 2007, 8:58 http://www.biomedcentral.com/1471-2199/8/58
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proteins are identical across 14 positions in the recogni-
tion helix (13 in DMRT7), whereas DMRT6 differs at six of
these 14 positions. One of these variant residues is an
arginine in the other DMRT proteins but a threonine in
DMRT6, and is the site of a known intersex mutation in
DSX (R91Q). Additionally, and perhaps more signifi-
cantly, within the zinc binding module, a conserved lysine
residue that in DSX has been proposed to form an impor-
tant salt bridge to the DNA backbone (K60), instead is
substituted with an alanine in DMRT6. We therefore sug-
gest that DMRT6 may not directly bind DNA. We cannot,
however, exclude the possibility that our in vitro condi-
tions are incompatible with DNA binding by DMRT6.
An important question is how closely the DNA binding
sites we have determined in vitro resemble those in vivo.
Particularly for the proteins that did not exhibit efficient
binding as homodimers, the sites occupied in vivo may
only partially resemble those determined in vitro. Ulti-
mately this question must be answered by identifying the
in vivo targets of the DMRT proteins. In flies and worms
DM domain proteins have been shown to use in vivo sites
that closely mirror their in vitro binding preferences: DSX
regulates transcription of the yolk protein gene Yp1 in flies
and MAB-3 regulates transcription of the yolk protein
gene vit-2 and the antineural bHLH gene ref-1 in worms
and this requires sites closely matching those preferred in
vitro [26,27,39]. These results suggest that at least some of
the DMRT proteins are likely to regulate their in vivo tar-
gets via sites similar to the ones we have defined.
Conclusion
Selection of DNA binding sites from random oligonucle-
otide pools demonstrates that mammalian DMRT pro-
teins prefer sequences similar to those bound by DSX of
Drosophila. Like DSX, the DMRT proteins have higher
sequence specificity than most minor groove DNA bind-
ing proteins. The preferred DMRT binding sites differ at a
few positions, and the differences can affect binding effi-
ciency. However, in some cases different DMRT proteins
can efficiently bind to the same sequence, so it is unlikely
that in vivo target gene specificity is governed only by
binding site sequences. DMRT proteins can heterodimer-
ize on DNA and in some situations bind more efficiently
as heterodimers than as homodimers. From this we con-
clude that heterodimer formation may contribute to tran-
scriptional regulation by DMRT proteins.
Methods
DNA binding site selection
DMRT protein coding sequences (except DMRT4) were
cloned into a derivative of T7βplink [40] that places a
9E10 Myc epitope tag at the amino terminus (pT7 Ntag
plink); the DMRT4 coding sequence was inserted into
another T7βplink derivative (pT7 plink Ctag) that places
the tag at the carboxy terminus. Proteins were produced
using the TNT™ Quick Coupled transcription/translation
system (Promega) according to the manufacturer's
instructions, except that 20 μM ZnSO4 was included. Site
selections were carried out essentially as described [34],
except that binding reactions contained 10 mM Tris-HCl
pH 7.9, 100 mM KCl, 10% glycerol, 5 mM MgCl2,
0.075%Triton-X-100, 1 mM DTT, 1 μg BSA, 0.1 μg dI-dC,
75 ng plasmid DNA (as a more complex non-specific
competitor), 0.2 ng radiolabeled duplex probe, and 4 μl
in vitro translation mix, in a total volume of 20 μl. After
co-incubation of the epitope-tagged proteins with the oli-
gonucleotide pools, complexes were recovered using a
mMACS™ epitope tag protein isolation kit (Miltenyi Bio-
tec #130-091-123). After each round of immunoprecipita-
tion we tested whether each protein formed shifted bands
in the gel mobility shift assay (see below), and cloned and
analyzed sites from the upper shifted band (presumed to
contain DMRT dimers) from the first round in which
shifted bands were apparent. We also confirmed, by anti-
body supershift, that each shifted band contained the pro-
tein of interest.
Site selection analysis
Sequences of selected oligonucleotides were compared
and any duplicates eliminated from the analysis.
Sequences were trimmed to retain 5 nucleotides of the
primer binding site on each side of the variable sequence.
Gibbs Motif Sampler [41] was used to align sequences. In
some DMRT selections the binding site in a small subset
of sequences overlapped for several base pairs in a consist-
ent way with the fixed primer binding site. These
sequences were not included in the final analysis. The
consensus sites encompass all nucleotide positions with a
Gibbs information content of 0.3 or greater (DSXF 13 bp,
DMRT1 15 bp, DMRT2 16 bp, DMRT3 15 bp, DMRT4 13
bp, DMRT5 15 bp, DMRT7 14 bp, see Additional file 1).
Fewer than 5% of oligonucleotides contained no discern-
ible site conforming to the preliminary consensus, and
these were excluded from the final analysis. Weblogo [42]
was used to generate representations of the consensus
sequences. To generate comparable Weblogo representa-
tions for Figure 2a, sequences flanking the consensus
sequence were included (see Additional file 1)
Gel mobility shift assay
(1RE) 5'-TCGAGATTTGATACATTGTTGC-3' and comple-
ment with overhanging XhoI ends were annealed by heat-
ing to 80°C for three minutes in 20 mM Hepes-KOH [pH
7.9], 50 mM NaCl, and 6 mM MgCl2; slow-cooled to
50°C; held at that temperature for ten minutes; and
cooled to room temperature. After annealing and cooling,
the duplex oligonucleotides were de-salted through a
Sephadex G-50 spin column. The de-salted duplexes were
labeled with Klenow DNA polymerase and α [32P]-dCTP.BMC Molecular Biology 2007, 8:58 http://www.biomedcentral.com/1471-2199/8/58
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Unincorporated nucleotides were removed through a
Sephadex G-50 spin column.
DNA binding reactions contained 10 mM Tris-HCl (pH
7.9), 100 mM KCl, 10% glycerol, 5 mM MgCl2, 1 mM
spermidine, 0.075%Triton-X-100, 1 mM DTT, 1 μg BSA,
0.1 μg dI-dC, 75 ng plasmid DNA (as a more complex
non-specific competitor), 0.5 ng radio-labeled duplex
probe, and 4 μl in vitro translation mix, in a total volume
of 20 μl. Binding reactions were performed on ice for ten
minutes and complexes were resolved on a 5% native acr-
ylamide (37.5:1) gel in 0.5× TB. Gels were run at 300 v for
1 hour and 45 minutes at 4°C, then dried and subjected
to autoradiography. Quantitation was performed using
the Molecular Dynamics PhosphoImager using the Image
quant software. For supershift and competition experi-
ments, the antibody or unlabeled competitor (40-fold
molar excess) was added at the start of the ice incubation.
Gel mobility shifts using testes nuclear extract, contained
4 μl testis extract, 225 ng non-specific competitor, and
omitted MgCl2.
For Figure 2 the top strand probes were
(1RE) 5'-TCGAGCCCGCAACAATGTTGCAAATC-3',
(2RE) 5'-TCGAGCGATACAATGTATCAATTTGC-3',
(3RE) 5'-TCGAGAACAATGTAACAATTTCGCCC-3',
(4RE) 5'-TCGAGAAAATGTAACAATTTAGCCGC-3',
(5RE) 5'-TCGAGCGCTACTGTTACATTGTCGCC-3',
(7RE) 5'-TCGAGTCTCAACAATGTAACAATTTC-3'
Each of these oligonucleotides was annealed to its com-
plement, with overhanging XhoI ends, and labeled as
described above.
Testis nuclear extracts
Extracts were prepared from sixteen 3.5 week old male
mice. Testes were rinsed in phosphate-buffered saline and
homogenized in 25 ml of extraction buffer (10 mM
Hepes-KOH [pH 7.9], 10 mM KCl, 0.1 mM EDTA, 0.74
mM spermidine, 1 mM DTT, 0.5 mM PMSF, 2 M sucrose)
with five strokes of a dounce homogenizer using the B
(loose) pestle. The homogenate was spun through a 10 ml
cushion of the same solution at 24 k rpm for 30 minutes
at 4°C in an SW28 rotor. After removal of the supernatant,
recovered nuclei were resuspended in 5 ml of extraction
buffer containing 0.42 M NaCl, 5 mM DTT, and protease
inhibitors, and stirred at 4°C for one hour. After pelleting
at 15 k rpm for 30 minutes in an SS-34 rotor, the supern-
antant was snap-frozen and stored at -70°C.
VP16 activation cell based assay
For Figure 2D, coding sequences for each of the DMRT
proteins were inserted into pKH68, an EF-1α promoter-
driven expression vector [43], generating constructs fusing
an SV40 nuclear localization signal, a Myc epitope tag,
and the VP16 strong transcriptional activation domain to
the N-terminus of the protein. For Figure 1E, coding
sequences for human DMRT1, the VP16 domain and a
Myc epitope tag were inserted into the T7/CMV promoter-
driven pCMX vector such that DMRT1 is N-terminal to the
VP16 activation domain and Myc tag. Luciferase reporter
plasmids were generated by inserting a single copy (or for
Figure 1E, four copies) of the consensus binding sequence
for each DMRT protein into the XhoI site of the reporter
plasmid pGL3-Promoter (Promega). Each VP16 fusion
plasmid was cotransfected into HEK293 cells with the
appropriate reporter plasmid and a CMV-lacZ plasmid
(for normalization of transfection efficiency). Luciferase
levels were compared to those of cells co-transfected with
each DMRT reporter plasmid and empty pKH68. The top
strand primers used to generate the reporter constructs
were the same as those used in the Figure 2 gel shift assays.
Mutagenesis
Mutants were generated using the GeneEditor™ system
from Promega according to the manufactures instruc-
tions. The primer used to generate the R123A mutant in
hDMRT1 was 5'-Phos-CAGGTGGCCCTGAGAGCGCAG-
CAGGCCCAGGA-3'.
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